Therapeutic Response

EGFR positive, Wild type HRAS, Wild type KRAS, and Wild type NRAS status confers therapeutic sensitivity to Cetuximab in combination with Fluorouracil and Oxaliplatin in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Erbitux (cetuximab) [product information]. EMA. The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.